Meeting slides
Suggested Readings

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, et al. Am Heart J. 2018;206:11-23.

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

DeFronzo RA, Norton L, Abdul-Ghani M. Nat Rev Nephrol. 2017;13(1):11-26.

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus.

Kato ET, Silverman MG, Mosenzon O, et al. Circulation. 2019;139(22):2528‐2536.

Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.

King RJ, Grant PJ. Herz. 2016;41(3):184-192.

Diabetes mellitus and heart failure.

Lehrke M, Marx N. Am J Cardiol. 2017; 120(suppl 1):S37-S47.

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology.

Maack C, Lehrke M, Backs J, et al. Eur Heart J. 2018;39(48):4243‐4254.

Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups.

Mahaffey KW, Jardine MJ, Bompoint S, et al. Circulation. 2019;140(9):739-750.

Dapagliflozin in patients with heart failure and reduced ejection fraction.

McMurray JJV, Solomon SD, Inzucchi SE, et al. N Engl J Med. 2019;381(21):1995-2008.

Canagliflozin and cardiovascular and renal events in type 2 diabetes.

Neal B, Perkovic V, Mahaffey KW, et al. N Engl J Med.2017;377(7):644-657.

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, Jardine MJ, Neal B, et al. N Engl J Med. 2019;380(24):2295-2306.

Timing of onset of clinical benefit with dapagliflozin in patients with heart failure: an analysis from the dapagliflozin and prevention of adverse-outcomes in heart failure trial (DAPA-HF).

Sabatine MS, DeMets DL, Inzucchi SE, et al. Circulation. 2019;140(25):e973.

Diabetic kidney disease.

Thomas MC, Brownlee M, Susztak K, et al. Nat Rev Dis Primers. 2015;1:15018.

SGLT2 inhibition in the diabetic kidney—from mechanisms to clinical outcome.

van Bommel EJ, Muskiet MH, Tonneijck L, et al. Clin J Am Soc Nephrol. 2017;12(4):700-710.

Empagliflozin and progression of kidney disease in type 2 diabetes.

Wanner C, Inzucchi SE, Lachin JM, et al. N Engl J Med. 2016;375(4):323-334.

Dapagliflozin and cardiovascular outcomes in type 2 diabetes.

Wiviott SD, Raz I, Bonaca MP, et al. N Engl J Med. 2019;380(4):347-357.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393(10166):31-39.

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.

Zinman B, Wanner C, Lachin JM, et al. N Engl J Med. 2015;373(22):2117-2128.

Related activities
1.00 CME/CE

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Faculty: Daniel Einhorn, MD, FACE, FACP; Serge A. Jabbour, MD, FACP, FACE; Marc S. Sabatine, MD, MPH; Kumar Sharma, MD
Release: 08/17/2020
Expiration: 08/17/2021